Abstract 7351: Financial toxicity and satisfaction with cancer treatment among patients with multiple myeloma: An analysis of the MMRF's CureCloud initiative

Abstract Background: Multiple myeloma (MM) is one of the most expensive cancers to treat and many patients with MM experience financial toxicity. However, there are limited studies of financial toxicity and its sequalae in this population. In this study, we aimed to explore financial toxicity in a national cohort of patients with MM. Moreover, we aimed to determine if financial toxicity was associated with satisfaction with one’s cancer treatment. Patients and Methods: This study analyzed data from the Multiple Myeloma Research Foundation (MMRF) CureCloud initiative (NCT03657251). CureCloud is a longitudinal study which collected biospecimens, clinical data, and patient reported outcomes (PROs), the COmprehensive Score for Financial Toxicity (COST) and the Cancer Therapy Satisfaction Questionnaire (CTSQ). Results: In total, 214 participants completed the PROs. The mean age was 68, 60% were male, and 94% were white. The median time from MM diagnosis to the baseline survey completion was 6 months. The mean COST score was 29 (SD=10) and 37% had a COST score less than 26 and were considered to be experiencing financial toxicity. Younger patients were more likely to be experiencing financial toxicity than older patients. For each 10 years decrease in age, the odds of financial toxicity increased by 52% (aOR 1.52; 95% CI 1.20-1.87; p<0.01). Patients who resided in less affluent neighborhoods were also more likely to be experiencing financial toxicity. For each $10, 000 decrease in median household income of one’s home census tract, the odds of financial toxicity increased by 87% (aOR 1.87; 95% CI 1.20-2.49; p=0.01). Participants experiencing financial toxicity had a mean CTSQ score 6.7 points lower than those without (b = -6.7; 95% CI [-2.7]-[-10.6]; p < 0.01). A subset of patients (n = 75) completed a second COST survey approximately one year later. Financial toxicity status was relatively stable; the status of 81% of patients was the same at both time points. In patients experiencing financial toxicity at baseline, 67% (18/27) were still experiencing it at the later time point. An additional 10% (5/48) of patients not experiencing financial toxicity at the initial survey were at the later time point. Conclusions: Over one-third of patients with MM experienced financial toxicity and financial toxicity was associated with reduced satisfaction with MM treatment. Younger patients and those who live in less affluent neighborhoods were more likely to experience financial toxicity. These segments of the MM population can be targeted for interventions aimed to reduce financial toxicity. Citation Format: Mark Aaron Fiala, Eva Lepisto, Chioma Amadi-Mgbenka, Jessica Schulman, George Mulligan, Hearn Cho. Financial toxicity and satisfaction with cancer treatment among patients with multiple myeloma: An analysis of the MMRF's CureCloud initiative [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 7351.